1. The production of malignant primary hepatic tumours in the rat by feeding dimethylnitrosamine;Magee;Br J Cancer,1956
2. ICH Guideline M7(R1) on Assessment and Control of DNA Reactive (Mutagenic) Impurities in Pharmaceuticals to Limit Potential carcinogenic Risk. EMA/CHMP/ICH/83812/2013. https://www.ema.europa.eu/en/documents/scientific-guideline/ich-guideline-m7r1-assessment-control-dna-reactive-mutagenic-impurities-pharmaceuticals-limit_en.pdf.
3. Short commentary on NDMA (N-nitrosodimethylamine) contamination of valsartan products;Snodin;Regul Toxicol Pharmacol,2019
4. Questions and answers for marketing authorization holders/applicants on CHMP Opinion for the Article 5(3) of Regulation (EC) No 726/2004 referral on nitrosamine impurities in human medicinal products EMA/CHMP/409815/2020 Rev. 11. 29 July 2022.https://www.ema.europa.eu/en/documents/referral/nitrosamines-emea-h-a53-1490-questions-answers-marketing-authorisation-holders/applicants-chmp-opinion-article-53-regulation-ec-no-726/2004-referral-nitrosamine-impurities-human-medicinal-products_en.pdf
5. Potential for the formation of N-nitrosamines during the manufacture of active pharmaceutical ingredients: an assessment of the risk posed by trace nitrite in water;Ashworth;Org Process Res Dev,2020